Precision Bio

Coming – November 11

Beyond CRISPR: The Next Frontier in Gene Editing

Date and Time

November 11

–

4:00 PM ET / 1:00 PM PT

Details will be shared with confirmed attendees

About this Event

Precision BioSciences | Executive Briefing with Michael Amoroso, President and CEO

Imagine a future where devastating genetic diseases can be treated at their source, potentially freeing patients from lifelong therapies and giving children facing shortened lives a different future.

Precision BioSciences (NASDAQ: DTIL) is working to make that future possible through ARCUS®, its proprietary gene-editing platform designed to precisely modify DNA and potentially deliver lasting therapeutic benefits.

Unlike companies relying on licensed gene-editing technology, Precision wholly owns its platform, offering potential advantages in precision, efficiency, development economics, and future licensing opportunities.

The company is advancing two important clinical programs:
  • Duchenne Muscular Dystrophy: A potentially transformative therapy designed to correct genetic mutations affecting approximately 60% of patients with this devastating childhood disease.
  • Chronic Hepatitis B: A treatment designed to directly target viral DNA, with encouraging early human clinical results supporting the potential for a functional cure.


    • With more than 75 issued patents, promising early clinical evidence, and significant milestones expected through 2027, Precision is approaching an important period in its development.

    Join FORCE Family Office for an Executive Briefing with Michael Amoroso, President and CEO of Precision BioSciences, as we explore the science behind ARCUS, the company’s clinical pipeline, and the potential to transform the treatment of serious diseases while creating substantial commercial opportunities.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.